Carregant...
Molecular Pathways: Maintaining MAPK inhibitor sensitivity by targeting non-mutational tolerance
Targeting hyperactive MAPK signaling has proven to be an effective treatment for a variety of different cancers. Responses to the BARF inhibitors vemurafenib or dabrafenib and MEK inhibitors trametinib or cobimentinib are however transient and complete remission is rarely observed; rather outgrowth...
Guardat en:
| Publicat a: | Clin Cancer Res |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5300098/ https://ncbi.nlm.nih.gov/pubmed/27797970 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0954 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|